tiprankstipranks
Trending News
More News >
Terminalcare Support Institute, Inc. (JP:7362)
:7362
Japanese Market

Terminalcare Support Institute, Inc. (7362) AI Stock Analysis

Compare
0 Followers

Top Page

JP

Terminalcare Support Institute, Inc.

(7362)

Rating:66Neutral
Price Target:
¥842.00
▲(7.81%Upside)
The overall stock score is primarily influenced by solid financial performance, despite challenges in cash flow management. Technical analysis indicates neutral momentum, and the reasonable valuation adds moderate support to the score. The exclusion of earnings call and corporate events data limits further insights.

Terminalcare Support Institute, Inc. (7362) vs. iShares MSCI Japan ETF (EWJ)

Terminalcare Support Institute, Inc. Business Overview & Revenue Model

Company DescriptionTerminalcare Support Institute, Inc. (7362) is a healthcare organization that specializes in providing comprehensive support services for terminally ill patients and their families. The company operates within the healthcare and social assistance sectors, focusing on enhancing the quality of life for individuals nearing the end of life through a range of tailored services, including palliative care, counseling, and support programs.
How the Company Makes MoneyTerminalcare Support Institute, Inc. generates revenue through a variety of channels, primarily through direct billing for its services to patients and their families. The company may also receive funding from insurance reimbursements, partnerships with healthcare providers, and government healthcare programs. In addition, it might engage in collaborations with hospitals and hospices to extend its reach and service offerings, ensuring a steady flow of referrals and engagements. These collaborations can also lead to grant opportunities or subsidies aimed at improving palliative care standards, further contributing to the company's income.

Terminalcare Support Institute, Inc. Financial Statement Overview

Summary
The company exhibits solid revenue growth and stable profitability with a 10.66% increase in revenue and a net profit margin of 2.40%. However, the increasing leverage with a Debt-to-Equity ratio of 2.14 and negative free cash flow indicate financial risks and potential cash flow management challenges.
Income Statement
75
Positive
The company has demonstrated consistent revenue growth, with a 10.66% increase from 2023 to 2024. Gross Profit Margin for 2024 was 14.08%, and Net Profit Margin was 2.40% indicating stable profitability levels. However, the EBIT and EBITDA margins show some variability, with EBIT Margin at 2.80% and EBITDA Margin at 5.29%, reflecting potential operating cost pressures.
Balance Sheet
70
Positive
The Debt-to-Equity Ratio has increased to 2.14, which suggests rising leverage levels. However, the Return on Equity (ROE) stands at 8.63%, showing effective utilization of equity for generating profits. The Equity Ratio is 27.29%, indicating a moderate equity base relative to total assets.
Cash Flow
60
Neutral
The Free Cash Flow has been negative, reflecting a challenging situation in managing capital expenditures with operational cash flows. The Operating Cash Flow to Net Income Ratio is 2.69, indicating strong cash generation relative to net income. However, the Free Cash Flow to Net Income Ratio is negative, pointing to cash flow management issues.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
4.71B4.25B4.10B3.40B2.93B
Gross Profit
664.67M646.76M685.84M599.50M464.84M
EBIT
132.86M110.54M193.50M172.26M89.02M
EBITDA
321.42M300.83M334.75M284.93M237.34M
Net Income Common Stockholders
113.77M126.67M157.54M138.03M102.29M
Balance SheetCash, Cash Equivalents and Short-Term Investments
1.13B1.38B1.09B874.72M411.85M
Total Assets
4.80B4.09B3.03B2.88B2.06B
Total Debt
2.81B2.26B1.34B1.43B1.44B
Net Debt
1.68B878.35M253.41M556.53M1.03B
Total Liabilities
3.49B2.90B1.95B1.95B1.82B
Stockholders Equity
1.31B1.19B1.08B927.37M237.34M
Cash FlowFree Cash Flow
-797.40M-597.43M303.05M-57.27M51.51M
Operating Cash Flow
304.51M238.18M812.73M462.19M124.89M
Investing Cash Flow
-1.10B-836.33M-510.68M-523.54M-74.58M
Financing Cash Flow
545.64M892.46M-90.11M523.02M-56.64M

Terminalcare Support Institute, Inc. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price781.00
Price Trends
50DMA
786.40
Negative
100DMA
832.19
Negative
200DMA
914.80
Negative
Market Momentum
MACD
-5.09
Negative
RSI
45.82
Neutral
STOCH
42.53
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7362, the sentiment is Negative. The current price of 781 is above the 20-day moving average (MA) of 780.55, below the 50-day MA of 786.40, and below the 200-day MA of 914.80, indicating a bearish trend. The MACD of -5.09 indicates Negative momentum. The RSI at 45.82 is Neutral, neither overbought nor oversold. The STOCH value of 42.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7362.

Terminalcare Support Institute, Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
78
Outperform
¥10.55B14.34
1.38%20.50%62.52%
76
Outperform
¥2.52B6.58
4.00%5.85%-22.29%
75
Outperform
¥3.05B9.58
3.11%4.85%4759.88%
72
Outperform
¥3.02B8.08
2.51%2.33%-0.96%
69
Neutral
¥10.60B19.16
1.19%21.97%-20.94%
66
Neutral
¥1.20B13.13
7.06%-27.80%
54
Neutral
$5.38B3.40-45.06%3.28%16.75%-0.02%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:7362
Terminalcare Support Institute, Inc.
778.00
-242.00
-23.73%
JP:2425
Care Service Co., Ltd.
802.00
-31.61
-3.79%
JP:7061
Japan Hospice Holdings Inc.
1,252.00
-243.58
-16.29%
JP:7129
Miahelsa Holdings Corporation
1,090.00
63.98
6.24%
JP:7133
HYUGA PRIMARY CARE Co.,Ltd.
1,476.00
-180.20
-10.88%
JP:9220
FB CARE SERVICE CO.,LTD.
997.00
30.80
3.19%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.